Cardiac Implications of Novel Wuhan Coronavirus (COVID-19)

Background on Coronavirus epidemic

- COVID-19 was first reported in late December 2019, originating in Wuhan, China
- COVID-19 is a betacoronavirus, like SARS and MERS, presenting as viral pneumonia with a wide range of acuity
- As of February 12, there are 45,204 confirmed cases and 1,117 confirmed deaths across 28 countries; COVID-19 appears to have greater infectivity and a lower case fatality rate when compared to SARS and MERS
- 99% of all cases are in mainland China, where despite aggressive containment efforts, case counts continue to rise rapidly

Early cardiac implications from case reports on Wuhan Coronavirus

- Early case reports suggest patients with underlying conditions are at higher risk for complications or mortality from COVID-19; up to 50% of hospitalized patients have a chronic medical illness
- 40% of hospitalized patients with confirmed COVID-19 patients have cardiovascular or cerebrovascular disease
- In a recent case report on 138 hospitalized COVID-19 patients, 19.6% of patients developed acute respiratory distress syndrome
  - 16.7% of patients developed arrhythmia; 7.2% developed acute cardiac injury
  - 8.7% of patients developed shock; 3.6% developed acute kidney injury
  - Rates of complication were universally higher for ICU patients
The first reported death was a 61-year-old male, with a long history of smoking, who succumbed to acute respiratory distress, heart failure, and cardiac arrest.

Early, unpublished first-hand reports suggest at least some patients develop myocarditis.

**Potential cardiac implications from analog viral respiratory pandemics**

- **Influenza analog**: In all influenza pandemics other than the 1918 flu, cardiovascular events surpassed all other causes of mortality, including superimposed pneumonia.

- **General viral analog**: Viral illness is a well-known destabilizing factor in chronic cardiovascular disease, a general consequence of the imbalance between infection-induced increased metabolic demand and reduced cardiac reserve. The viral infection along with superimposed pneumonia will directly and indirectly affect the cardiovascular system.
  - Both coronary artery disease and heart failure patients are at increased risk of acute events or exacerbation; viral illness can potentially destabilize coronary plaques through several mechanisms including systemic inflammatory responses which have been recently documented with COVID-19.
  - Multiple co-morbidities (DM, obesity, HTN, COPD, CKD) further increase risk.

- **SARS/MERS analog**: Although published literature on CV implications of SARS/MERS is limited, in the absence of more detailed reporting on COVID-19, it may prove instructive.
  - 60% of MERS cases had one or more pre-existing comorbidity, resulting in a poorer prognosis; expert guidance suggests patients with diabetes, CVD, or renal disease should be prioritized for treatment.
  - Both SARS and MERS have been linked to acute myocarditis, acute myocardial infarction, and rapid-onset heart failure.
    - In one early published report, 2 out of the 5 deaths were attributed to MI.
    - These data should be interpreted cautiously—indicative of the increased CV risk in coronavirus patients, but not generalizable to broader outcomes.
  - Reversible, sub-clinical diastolic LV impairment in acute SARS even among those without underlying cardiac disease appears common, likely the result of systemic inflammatory immune response and is not unique to SARS; however, lower EF upon admission was predictive of later mechanical ventilation.
In one study of cardiovascular complications of SARS in 121 patients:  
- 71.9% of patients developed persistent tachycardia, including 40% with continued tachycardia during outpatient follow-up  
- 50.4% of patients developed sustained asymptomatic hypotension during hospitalization; one patient required inotropic support  
- 14.9% of patients developed transient bradycardia  
- 10.7% of patients developed transient cardiomegaly, without signs or symptoms of heart failure  
- One patient experienced transient paroxysmal AF, with spontaneous resolution  
- Cardiovascular complications appeared statistically uncorrelated with oxygen desaturation or ICU admission

Clinical guidance given current COVID-19 uncertainty

- COVID-19 is spread through droplets and can live for substantial periods outside the body; containment and prevention using standard public health and personal strategies for preventing the spread of communicable disease remains the priority  
- In geographies with active COVID-19 transmission (mainly China), it is reasonable to advise patients with underlying cardiovascular disease of the potential increased risk and to encourage additional, reasonable precautions  
- Older adults are less likely to present with fever, thus close assessment for other symptoms such as cough or shortness of breath is warranted  
- Some experts have suggested that the rigorous use of guideline-directed, plaque stabilizing agents could offer additional protection to CVD patients during a widespread outbreak (statins, beta blockers, ACE inhibitors, ASA); however, such therapies should be tailored to individual patients  
- It is important for patients with CVD to remain current with vaccinations, including the pneumococcal vaccine given the increased risk of secondary bacterial infection; it would also be prudent to receive influenza vaccination to prevent another source of fever which could be initially confused with coronavirus infection  
- It may be reasonable to triage COVID-19 patients according to the presence of underlying cardiovascular, respiratory, renal, and other chronic diseases for prioritized treatment  
- Providers are cautioned that classic symptoms and presentation of AMI may be overshadowed in the context of coronavirus, resulting in underdiagnosis
• For CVD patients in geographies without widespread COVID-19 emphasis should remain on the threat from influenza, the importance of vaccination and frequent handwashing, and continued adherence to all guideline-directed therapy for underlying chronic conditions

• COVID-19 is a fast-moving epidemic with an uncertain clinical profile; providers should be prepared for guidance to shift as more information becomes available

Expert Advisors

Mohammad Madjid, MD, MS, FACC, FSCAI
Assistant Professor of Medicine
McGovern Medical School
University of Texas at Houston Health Science Center
Memorial Hermann Heart and Vascular Institute

Scott D Solomon, MD, FACC
The Edward D. Frohlich Distinguished Chair
Professor of Medicine
Harvard Medical School
Brigham and Women’s Hospital

Orly Vardeny, PharmD, MS, FAHA, FHFA
Minneapolis VA Center for Care Delivery and Outcomes Research
Associate Professor of Medicine
University of Minnesota

Correspondence

Brendan Mullen, EVP, Science & Quality, American College of Cardiology
bmullen@acc.org

Reviewed and Approved

February 12, 2020 ACC Science and Quality Oversight Committee